Literature DB >> 7128006

Methadone plasma protein binding: alterations in cancer and displacement from alpha 1-acid glycoprotein.

F P Abramson.   

Abstract

Because of their elevated concentrations of plasma alpha 1-acid glycoprotein (AAG), cancer patients had a lower free fraction of methadone in plasma than did members of a control group. This difference was not great (-20%), but there was a fourfold variation in free fraction among a group of 13 patients (0.064 to 0.23). The bound/free methadone concentration ratio correlated linearly with plasma AAG. The binding of methadone to AAG was characterized by two classes of binding sites, the more avid having an association constant of 4 X 10(5)M-1 and an N of 0.38. Methadone could be displaced from AAG binding sites by a number of drugs: propranolol, chlorpromazine, prochlorperazine, thioridazine, and imipramine. The concentrations required for significant displacement (27 microM), as well as the relatively low Ka for methadone, suggest that the free fraction of methadone will not be significantly affected by elevated methadone concentrations or through displacement by other drugs that also bind to AAG.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7128006     DOI: 10.1038/clpt.1982.217

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

1.  Methadone use in children and young adults at a cancer center: a retrospective study.

Authors:  Doralina L Anghelescu; Lane G Faughnan; Gisele M Hankins; Deborah A Ward; Linda L Oakes
Journal:  J Opioid Manag       Date:  2011 Sep-Oct

Review 2.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

3.  Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model.

Authors:  Feng Yang; Xianping Tong; D Gail McCarver; Ronald N Hines; Daniel A Beard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-07       Impact factor: 2.745

4.  [Not Available].

Authors:  J Jage
Journal:  Schmerz       Date:  1989-09       Impact factor: 1.107

5.  Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein.

Authors:  C B Eap; C Cuendet; P Baumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-02       Impact factor: 3.000

Review 6.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Differential effect of cancer on the serum protein binding to mianserin and imipramine.

Authors:  I Torres; E Suárez; J M Rodríguez-Sasiain; C Aguirre; R Calvo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Apr-Jun       Impact factor: 2.441

Review 9.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

10.  Dose, Plasma Level, and Treatment Outcome Among Methadone Patients in Shanghai, China.

Authors:  Haifeng Jiang; Maureen Hillhouse; Jiang Du; Shujun Pan; Ang Alfonso; Jun Wang; Zhirong Zhou; Weijun Yuan; Walter Ling; Min Zhao
Journal:  Neurosci Bull       Date:  2016-09-10       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.